PTN - PALATIN TECHNOLOGIES INC

21.5
-0.720   -3.349%

Share volume: 6,913
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$22.22
-0.72
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 28%
Dept financing 23%
Liquidity 47%
Performance 9%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
4.62%
1 Month
15.90%
3 Months
26.84%
6 Months
113.93%
1 Year
113.93%
2 Year
1,101.12%
Key data
Stock price
$21.50
P/E Ratio 
0.00
DAY RANGE
$20.98 - $22.36
EPS 
$1.44
52 WEEK RANGE
$6.91 - $31.00
52 WEEK CHANGE
$113.93
MARKET CAP 
26.187 M
YIELD 
N/A
SHARES OUTSTANDING 
1.772 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,392
AVERAGE 30 VOLUME 
$15,529
Company detail
CEO: Carl Spana
Region: US
Website: palatin.com
Employees: 30
IPO year: 1997
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Palatin Technologies, Inc. develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the. treatment of premenopausal women with hypoactive sexual desire disorder.

Recent news